Dashboard for the Leading Network of Stock Market and Personal Finance Blogs

Visit Seeking Alpha

China Biotech Week in Review: Deals and Drugs

Posted on June 15, 2008

Last week, the news item that could have the most profound effect on the China biomedical world, did not paradoxically involve a China biomedical company. The third largest pharmaceutical company in Japan, Daiichi Sankyo [TSE: 4568.JP], announced its intention to buy a majority stake in Ranbaxy [NSE/BSE: Ranbaxy/500359], the generic drug maker that is the largest pharmaceutical company in India (see story). The purchase price could reach as much as $4.6 billion. A comparison between India and China drug markets turns up many differences the Indian firms are more mature with larg...

Original article link


biotech , clinical trial , disease , health , markets , pharma , system